2020
DOI: 10.3390/ijms21207539
|View full text |Cite
|
Sign up to set email alerts
|

Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma

Abstract: Multiple myeloma (MM) is a cancerous bone disease characterized by malignant transformation of plasma cells in the bone marrow. MM is considered to be the second most common blood malignancy, with 20,000 new cases reported every year in the USA. Extensive research is currently enduring to validate diagnostic and therapeutic means to manage MM. microRNAs (miRNAs) were shown to be dysregulated in MM cases and to have a potential role in either progression or suppression of MM. Therefore, researchers investigated… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
17
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 16 publications
(18 citation statements)
references
References 190 publications
(222 reference statements)
0
17
1
Order By: Relevance
“…In their mature form, miRNAs are about 19–22 nucleotides in length and are able to regulate the expression of messenger RNAs [ 11 ] and long non-coding RNAs [ 12 ]. Importantly, miRNA expression is disrupted in a vast number of diseases and hematological malignancies, such as MM [ 13 , 14 ]. Specifically, miRNAs are involved in MM onset and progression, which triggered their study as therapeutic targets [ 14 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…In their mature form, miRNAs are about 19–22 nucleotides in length and are able to regulate the expression of messenger RNAs [ 11 ] and long non-coding RNAs [ 12 ]. Importantly, miRNA expression is disrupted in a vast number of diseases and hematological malignancies, such as MM [ 13 , 14 ]. Specifically, miRNAs are involved in MM onset and progression, which triggered their study as therapeutic targets [ 14 ].…”
Section: Introductionmentioning
confidence: 99%
“…Specifically, miRNAs are involved in MM onset and progression, which triggered their study as therapeutic targets [ 14 ]. Since the last two decades, circulating (extracellular) miRNAs have emerged as potential biomarkers for a wide range of diseases [ 11 , 15 ], including for MM [ 13 ]. Considering miRNAs can be detected in human blood serum/plasma, urine, saliva and other body fluids [ 11 ], these molecules are promising diagnosis tools through non-invasive or minimally invasive methods [ 15 ], leading to the development of several miRNA-based products for disease diagnosis.…”
Section: Introductionmentioning
confidence: 99%
“…They may act as tumor oncogenes or tumor suppressor genes to either enhance or impede tumor growth, respectively. We have previously elaborated the potential role of miRNAs in the diagnosis and prognosis of MM [ 50 ]. MiRNAs can potentially serve as molecular biomarkers for MM due to the variable miRNAs detected at different stages of the diseases, therefore providing insights into the diagnosis/prognosis of MM patients [ 51 , 52 , 53 , 54 , 55 ].…”
Section: Novel Biomarkers For Diagnosis and Prognosis Of MMmentioning
confidence: 99%
“…Inhibition of oncogenic miRNAs can be achieved by antagomiRs, which are antisense miRNA molecules, or by miRNA-sponges (e.g., circular RNAs [ 130 ]) that are molecules that act as competing endogenous RNAs and thus are able to bind the miRNA and prevent it from binding to the target mRNA. Tumor-suppressor miRNAs can be therapeutically replaced by using viral and non-viral vectors and miRNA mimics [ 21 ]. Regarding MMBD there are many promising molecules that can serve as targets for miRNA targeted therapy.…”
Section: Conclusion and Future Perspectivesmentioning
confidence: 99%
“…A single miRNA displays multiple mRNA targets [ 18 ]. miRNA expression is deregulated in a variety of cancers [ 19 ], and hematological malignancies [ 20 ], including multiple myeloma [ 21 ]. Their role can be characterized as either oncogenic or oncosuppressive.…”
Section: Introductionmentioning
confidence: 99%